Clinical trials: Flu-like Syndrome

Multiple Sclerosis, Relapsing-Remitting

A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis

• Completed
• Age: 18 to 60 years
• Phase 4
• Results posted

This is an open-label, multi-center, 12-week, randomized, controlled, parallel group, Phase 4 study to assess whether the morning administration of interferon beta 1a (Rebif®) leads to a lower severity of flu-like symptoms (FLS)…

Trial name

RELIEF (NCT02064816)

Testing

Rebif®

Where

Germany

Volunteers

200 people

Sponsor

Merck KGaA, Darmstadt, Germany